跳至主要内容
临床试验/EUCTR2012-004053-88-GB
EUCTR2012-004053-88-GB进行中(未招募)1 期

Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents - EuroNet-PHL-C2

Justus Liebig Universität Gießen0 个研究点目标入组 2,200 人开始时间: 2018年5月22日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
2,200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •* Histologically confirmed primary diagnosis of classical Hodgkin’s lymphoma
  • •* Patients under 18 years of age on the date of written informed consent. In specialised Teenage and Young Adult (TYA) units in France, Italy and UK patients under 25 years of age can also be enrolled. Lower age limits will be country specific according to national laws or formal insurance requirements that may preclude very young Patients.
  • •* Written informed consent of the Patient and/or the Patient’s Parents or Guardian according to national laws
  • •* Negative pregnancy test within 2 weeks prior to starting treatment for female Patients with childbearing potential
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 0
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range 0

排除标准

  • •Patients with one or more of the following criterion are excluded:
  • •* Prior chemotherapy or radiotherapy for other malignancies
  • •* Pre-treatment of Hodgkin’s lymphoma (except for 7-10 days steroid pre-phase of a large mediastinal tumour)
  • •* Diagnosis of lymphocyte-predominant Hodgkin’s lymphoma
  • •* Other (simultaneous) malignancies
  • •* Contraindication or known hypersensitivity to study drugs
  • •* Severe concomitant diseases (e.g. immune deficiency syndrome)
  • •* Known HIV-positivity
  • •* Residence outside the participating countries where long term follow-up cannot be guaranteed
  • •* Pregnancy and/or lactation
  • •* Patients who are sexually active and are unwilling to use adequate contraception during therapy and for one year after last trial treatment
  • •* Current or recent (within 30 days prior to date of written informed consent) treatment with another investigational drug or participation in another interventional clinical trial

研究者

相似试验